Vanda Pharmaceuticals has been granted a patent for using a melatonin agonist to treat circadian rhythm disorders, including in blind patients. The method involves administering tasimelteon to agonize specific receptors in the patient. GlobalData’s report on Vanda Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Vanda Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Vanda Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. Vanda Pharmaceuticals's grant share as of February 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of circadian rhythm disorder using tasimelteon